Pharmacokinetics and Pharmacodynamics of Lurasidone Hydrochloride, a Second-Generation Antipsychotic: A Systematic Review of the Published Literature

@article{Greenberg2016PharmacokineticsAP,
  title={Pharmacokinetics and Pharmacodynamics of Lurasidone Hydrochloride, a Second-Generation Antipsychotic: A Systematic Review of the Published Literature},
  author={William M Greenberg and Leslie Citrome},
  journal={Clinical Pharmacokinetics},
  year={2016},
  volume={56},
  pages={493-503}
}
Lurasidone hydrochloride, a benzisothiazol derivative, is a second-generation (atypical) antipsychotic agent that has received regulatory approval for the treatment of schizophrenia in the US, Canada, the EU, Switzerland, and Australia, and also for bipolar depression in the US and Canada. In addition to its principal antagonist activity at dopamine D2 and serotonin 5-HT2A receptors, lurasidone has distinctive 5-HT7 antagonistic activity, and displays partial agonism at 5-HT1A receptors, as… Expand
Lurasidone – pharmacodynamic and pharmacokinetic properties, clinical potential and interaction risk
Lurasidone is a novel second-generation antipsychotic approved for the treatment of schizophrenia and bipolar depression in adults. It displays high affinity for D2 and 5-HT2A and 5-HT7 receptors,Expand
Lurasidone: efficacy and safety in the treatment of psychotic and mood disorders
TLDR
Available research findings indicate that LRSD is effective and well-tolerated for short-term treatment of schizophrenia, and for acute bipolar depression, but its risk of akathisia may exceed that of other modern antipsychotics. Expand
Practical Guidance on the Use of Lurasidone for the Treatment of Adults with Schizophrenia
TLDR
Given the crucial importance of addressing the physical as well as mental healthcare needs of patients, lurasidone is a rational therapeutic choice for adults with schizophrenia, both in the acute setting and over the long term. Expand
Sustained Impairment of Lurasidone Clearance After Discontinuation of Posaconazole: Impact of Obesity, and Implications for Patient Safety
TLDR
This study evaluated the time-course of recovery from the posaconazole drug interaction, and the effect of obesity on the recovery process, and recommended requiring normal-weight and obese patients to limit the dosage of lurasidone, or undergo a washout period, for two and three weeks, respectively, after discontinuation of posaconzole. Expand
The Effect of Chronic Treatment with Lurasidone on Rat Liver Cytochrome P450 Expression and Activity in the Chronic Mild Stress Model of Depression
TLDR
It can be suggested that the metabolism of endogenous substrates and drugs, catalyzed by the isoforms CYP 2B, CYP2C11, or CYP3A, may proceed at a different rate in the two groups of animals (nonstressed and stressed) in the rat CMS model. Expand
Identification of clinical phenotypes in schizophrenia: the role of lurasidone
TLDR
It is established that lurasidone is suggested at any age, with no gender difference, at all stages of the disease, and is among the best-tolerated antipsychotics, and its use is indicated in the presence of different comorbidities. Expand
The atypical neuroleptics iloperidone and lurasidone inhibit human cytochrome P450 enzymes in vitro. Evaluation of potential metabolic interactions
TLDR
The obtained results indicate that metabolic/pharmacokinetic interactions with iloperidone (involving mainly CYP3A4 and CYP2D6 and possibly with lurasidone) andpossibly with CYP1A2, CYP 2C9 or CyP2C19 may occur during combined therapy. Expand
Asenapine, iloperidone and lurasidone exposures in young children reported to U.S. poison centers
TLDR
It is suggested that in children under 6 years of age, lurasidone exposures were least serious and iloperidones exposures were most serious based on clinical effects, management sites and coded outcomes. Expand
Combined in silico and in vitro approaches identified the antipsychotic drug lurasidone and the antiviral drug elbasvir as SARS-CoV2 and HCoV-OC43 inhibitors
TLDR
A pipeline based on in silico docking of known drugs on Sars-CoV1 and 2 RNA-dependent RNA polymerase combined with in vitro antiviral assays on both SARS- coV2 and the common cold human coronavirus HCoV-OC43 showed promising activity in the low micromolar range against both viruses with good selectivity index. Expand
Lurasidone in the Treatment of Bipolar Depression: Systematic Review of Systematic Reviews
TLDR
This overview stipulates the effectiveness of lurasidone in the acute treatment of Type I bipolar depression overall, and recommendations for future research should include further controlled trials of extended duration. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 79 REFERENCES
Critical appraisal of lurasidone in the management of schizophrenia
Lurasidone is a new atypical antipsychotic in the benzoisothiazoles class of chemicals. Like most second-generation antipsychotics it is a full antagonist at dopamine D2 and serotonin 5-HT2AExpand
Lurasidone for schizophrenia: a brief review of a new second-generation antipsychotic.
  • L. Citrome
  • Psychology, Medicine
  • Clinical schizophrenia & related psychoses
  • 2011
TLDR
Lurasidone is a second-generation antipsychotic newly approved by the U.S. Food and Drug Administration for the treatment of schizophrenia associated with minimal weight gain and no clinically meaningful alterations in glucose, lipids, or the ECG QT interval. Expand
Lurasidone: a new drug in development for schizophrenia
TLDR
Phase II efficacy data indicate that lurasidone doses from 40 to 120 mg/day are effective in the treatment of schizophrenia, with positive symptom reduction exceeding that for negative symptoms, as seen with other antipsychotics. Expand
Pharmacokinetics of lurasidone, a novel atypical anti-psychotic drug, in rats
TLDR
To characterise the pharmacokinetics of lurasidone, a new atypical anti-psychotic drug, in rats after intravenous and oral administration at dose range 0.5–2.5 and 2.5-10 mg/kg, lurasidsone showed dose-independent Pharmacokinetics and appeared to be primarily eliminated by its metabolism. Expand
The pharmacodynamic properties of lurasidone and their role in its antidepressant efficacy in bipolar disorder
TLDR
Whether the pharmacodynamic properties of lurasidone fit to a previously developed model which was the first to be derived on the basis of the strict combination of clinical and preclinical data with no input from theory or opinion is investigated. Expand
Lurasidone drug-drug interaction studies: a comprehensive review
TLDR
Lurasidone PK is altered by strong cytochrome P450 (CYP) 3A4 inhibitor or inducers, and coadministration is contraindicated; whereas moderate CYP3A4 inhibitors have less effect, and lurasid one dosage restrictions are recommended. Expand
Vilazodone: a brief pharmacological and clinical review of the novel serotonin partial agonist and reuptake inhibitor
TLDR
Vilazodone will lend itself to the current armamentarium in the treatment of major depressive disorder and may hold promise for patients who cannot tolerate other antidepressants, and its unique SPARI mechanism of action could also be efficacious for Patients who do not respond to SSRI or SNRI antidepressant monotherapies. Expand
Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo
TLDR
It is discovered that amisulpride was a potent competitive antagonist at 5-HT7a receptors and that interactions with no other molecular target investigated in this paper could explain its antidepressant actions in vivo. Expand
Pharmacokinetics and Tolerability of Lurasidone in Children and Adolescents With Psychiatric Disorders.
TLDR
Results suggest that lurasidone doses <120 mg/d were better tolerated compared with higher doses, especially in younger children, as well as dose proportional in the range of 20 to 160mg/d after the administration of single and multiple doses. Expand
Lurasidone in Schizophrenia: New Information About Dosage and Place in Therapy
TLDR
The totality of the evidence supports the overall tolerability of lurasidone, with minimal weight gain and no clinically-meaningful alterations in glucose, lipids, or the electrocardiogram corrected QT (ECG QTc) interval. Expand
...
1
2
3
4
5
...